Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Use of bio-banks in the EurocanPlatform

Prof Peter Riegman – Erasmus Medical Centre, Rotterdam, Netherlands
Use of bio-banks in the EurocanPlatform ( Prof Peter Riegman – Erasmus Medical Centre, Rotterdam, Netherlands )
18 May 2012

New approaches to personalised medicine

Prof Jens Ricke – Otto-Von-Guericke-University, Magdeburg, Germany
New approaches to personalised medicine ( Prof Jens Ricke – Otto-Von-Guericke-University, Magdeburg, Germany )
18 May 2012

Recent developments in neoadjuvant therapy

Prof Gunter Von Minckwitz – German Breast Group, Neu-Isenburg, Germany
Recent developments in neoadjuvant therapy ( Prof Gunter Von Minckwitz – German Breast Group, Neu-Isenburg, Germany )
17 May 2012

Highlights and goals of IMPAKT 2012

Prof Martine Piccart – Jules Bordet Institute, Brussels, Belgium
Highlights and goals of IMPAKT 2012 ( Prof Martine Piccart – Jules Bordet Institute, Brussels, Belgium )
17 May 2012

PI3K and the heterogeneity of small tumour breast cancer

Dr Sherene Loi – Jules Bordet Institute, Brussels, Belgium
PI3K and the heterogeneity of small tumour breast cancer ( Dr Sherene Loi – Jules Bordet Institute, Brussels, Belgium )
17 May 2012

Molecularly characterising triple negative breast cancer

Prof Jorge Reis-Filho – Jules Bordet Institute, Brussels, Belgium
Molecularly characterising triple negative breast cancer ( Prof Jorge Reis-Filho – Jules Bordet Institute, Brussels, Belgium )
17 May 2012

Endocrine therapy and endocrine resistant breast cancer

Prof Mitch Dowsett – The Institute for Cancer Research, London, UK
Endocrine therapy and endocrine resistant breast cancer ( Prof Mitch Dowsett – The Institute for Cancer Research, London, UK  )
17 May 2012

Neoadjuvant therapy and PCR through chemotherapy prior to surgery

Dr Michail Ignatiadis – Jules Bordet Institute, Brussels, Belgium
Neoadjuvant therapy and PCR through chemotherapy prior to surgery ( Dr Michail Ignatiadis – Jules Bordet Institute, Brussels, Belgium )
17 May 2012

Minimising recurrence by using most effective treatment

Prof Fabrice Andre – Institut Gustave Roussy, Paris, France
Minimising recurrence by using most effective treatment ( Prof Fabrice Andre – Institut Gustave Roussy, Paris, France )
17 May 2012

Overcoming drug resistance and targeting critical pathways

Dr Larry Norton – Memorial Sloan-Kettering Cancer Center, New York, USA
Overcoming drug resistance and targeting critical pathways ( Dr Larry Norton – Memorial Sloan-Kettering Cancer Center, New York, USA )
17 May 2012

Heterogeneity of tumours and the challenges of biomarker development

Prof Giuseppe Curigliano – European Institute of Oncology, Milan, Italy
Heterogeneity of tumours and the challenges of biomarker development ( Prof Giuseppe Curigliano – European Institute of Oncology, Milan, Italy )
17 May 2012

Targeting the PI3K/mTOR pathway

Dr Lewis Cantley – Dana-Farber Cancer Institute, Boston, USA
Targeting the PI3K/mTOR pathway ( Dr Lewis Cantley – Dana-Farber Cancer Institute, Boston, USA )
17 May 2012